Table 4.
Determination of the studied drugs in pharmaceutical dosage forms by the proposed HPLC–DAD method and application of standard addition technique
| Pharmaceutical dosage form | HCT | VAL | AML | ATN | AMI | CAN |
|---|---|---|---|---|---|---|
| Exforge HCT® Tablets, B.N. A518682, Each tablet is labelled to contain 25.0 mg HCT, 160.0 mg VAL & 10.0 mg AML | ||||||
| % Found ± SD a | 99.73 ± 0.88 | 99.47 ± 0.59 | 99.85 ± 0.56 | – | – | – |
| Standard addition b % recovery of the pure added ± SD c | 98.45 ± 0.77 | 99.98 ± 0.37 | 99.31 ± 0.30 | – | – | – |
| Atenoretic® Tablets, B.N.71047, Each tablet is labelled to contain 25.0 mg HCT, 50.0mg ATN & 2.5 mg AMI | ||||||
| % Found ± SD a | 99.66 ± 0.77 | – | 100.95 ± 0.25 | 99.13 ± 0.65 | – | |
| Standard addition b % recovery of the pure added ± SD d | 100.54 ± 0.52 | – | – | 99.83 ± 1.03 | 99.41 ± 0.69 | – |
| Atacand plus® Tablets, B.N. 19015, Each tablet is labelled to contain 12.5 mg HCT, & 16.0 mg CAN | ||||||
| % Found ± SD a | 99.23 ± 0.57 | – | – | – | – | 98.80 ± 0.94 |
| Standard addition b % recovery of the pure added ± SD e | 98.73 ± 1.04 | – | – | – | – | 98.70 ± 0.68 |
a Average of three experiments
b Average of three experiments
c Claimed Concentration; 32 µg/mL VAL, 1 µg/mL AML and 2.5 µg/mL HCT and pure added equivalent to 8.0, 16.0, 32.0 µg/mL VAL, 0.5, 1.0, 2.0 µg/mL AML and 1.0, 2.5, 5.0 µg/mL HCT
d Claimed Concentration; 1.25 µg/mL AML, 25 µg/mL ATN and 12.5 µg/mL HCT and pure added equivalent to 0.5, 1.25,2.5 µg/mL AML,12.5, 25.0, 50.0 µg/mL ATN and 6.0, 12.5, 25.0 µg/mL HCT
e Claimed Concentration; 16 µg/mL CAN and 12.5 µg/mL HCT and pure added equivalent to8.0, 16.0, 32.0 µg/mL CAN and 6.0, 12.5, 25.0 µg/mL HCT